Infant Health

2023 fall–winter is the first season when vaccines for all three major respiratory viruses are available

Clinical trial findings establish methotrexate as the gold standard treatment for atopic dermatitis in children

 Approximately 1 in 500 newborns benefited from gene panel sequencing integration into first-tier screening tests

According to the CDC, RSV is the leading cause of infant hospitalization in the US and warrants immediate preventive action

New immunization is the first approved and recommended in the US to prevent severe RSV disease in all infants

Beyfortus proved to be safe and efficacious in trials with infants at varying degrees of risk for RSV infection

Pediatric hospitalizations for RSV infection in 2021–2022 equaled nearly half of all such hospitalizations in the past five years

Phase 1b trial of INZ-701 aimed to improve quality of life in patients with rare, genetic diseases 

A breakthrough RNA-monitoring method enables early detection of early-onset atopic dermatitis using sebum biomarkers

First-tier screening test measures total homocysteine levels in newborns to accurately identify HCU-positive samples